Printing must be done in color for the color cases, to up-scale their effectiveness. On November 22, 2013, the direct-to-consumer genet ic testing provider, 23andMe, recieved a letter from the U.S. Food and Drug Administration (FDA) ordering the company to restrict the sale and promotion of its genetic testing kit. The FDA said the merchandise was advertised as a preventative and diagnostic tool and that it was subject to the bureau's regulations for medical devices. Company co-founder Anne Wojcicki and chairman Andy Page attentively considered the possible impact of the FDA's letter on 23andMe's position in the business and the sustainability of its own operations.
PUBLICATION DATE: January 27, 2014 PRODUCT #: 514086-HCC-ENG
This is just an excerpt. This case is about SALES & MARKETING
Related Case Solutions & Analyses:
MediaMath: Positioning a Real-Time Interface for Online Media Planning & Buying
So Long to SingleStop? (B): Epilogue
Olympic Rent-A-Car U.S.: Customer Loyalty Battles
Strategic Complements and Substitutes
3D PRINTING
Gillette’s Launch of Sensor
General Food: Opportunities in Dog Food Market
Governance of World Association Football
Regression Analysis – Residential Real Estate
Wipro: Building a Global B-2-B Brand
